Cancer of Unknown Primary Site

Seminars in Oncology

Volumn 37, Issue 2, 2010, Pages 71-79

  Morris, Gloria J ^a   Greco, Frank A ^a   Hainsworth, John D ^a   Engstrom, Paul F ^a   Scialla, Salvatore ^a   Jordan III, W Edward ^a   Thomas, Lisa C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CA 19-9 ANTIGEN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 20; CYTOKERATIN 7; CYTOKERATIN AE1; CYTOKERATIN AE3; GEMCITABINE;

ADULT; AGED; ARTICLE; BACKACHE; BILE DUCT CARCINOMA; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; GALLBLADDER CANCER; HUMAN; HUMAN TISSUE; HYDRONEPHROSIS; IMMUNOHISTOCHEMISTRY; INGUINAL HERNIA; KIDNEY DYSFUNCTION; LYMPHADENOPATHY; MALE; MEDIASTINUM LYMPHADENOPATHY; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NODULAR GOITER; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; UROGENITAL TRACT TUMOR;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; RETROPERITONEAL NEOPLASMS;

EID: 77952343219     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.03.009     Document Type: Article

References (38)

1. Greco F.A., and Hainsworth J.D. Cancer of unknown primary site. In: DeVita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 8th ed. (2008), Lippincott Williams & Wilkins, Philadelphia 2363-2387
2. Greco F.A. Tumors of unknown origin. CA Cancer J Clin 42 (1992) 96-115
3. Hillen H.F.P. Unknown primary tumours. Postgrad Med J 76 (2000) 690-693
4. Bugat R., Bataillard A., Lesimple T., et al. Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 89 Suppl 1 (2003) S59-S66
5. Blaszyk H., Hartmann A., and Bjornsson J. Cancer of unknown primary: clinicopathologic correlations. APMIS 111 (2003) 1089-1094
6. Pavlidis B., Briasoulis E., and Hainsworth D. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39 (2003) 1990-2005
7. Van de Wouw A.J., Jansen R.L.H., Speel E.J., et al. The unknown biology of the unknown primary tumor: a literature review. Ann Oncol 14 (2003) 191-196
8. Pavlidis N., and Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 54 (2005) 243-250
9. Briasoulis E., Tsokos M., Fountzilas G., et al. Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: biological and clinical implications. A Hellenic Co-operative Oncology Group study. Anticancer Res 18 (1998) 1907-1919
10. Oien K.A. Pathologic evaluation of unknown primary cancer. Semin Oncol 36 (2009) 8-37
11. Summersgill B., Goker H., Ocin P., et al. Establishing germ cell origin of undifferentiated tumors by identifying gain of 12p material using comparative genomic hybridization analysis of paraffin-embedded samples. Diagn Mol Pathol 7 (1998) 260-266
12. Pittman K.B., Oliver I.N., Koczwara R., et al. Gemcitabine and carboplatin in carcinoma of unknown primary site. A phase II Adelaide Cancer Trials and Education Collaborative Study. Br J Cancer 95 (2006) 1309-1313
13. Greco F.A., and Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol 36 (2009) 65-74
14. Culine S. Prognostic factors in unknown primary cancer. Semin Oncol 36 (2009) 60-64
15. Sandler A.B., Gray R., Perry M., et al. Paclitaxel-carboplatin alone or with bevacizumab for non small cell lung cancer. N Engl J Med 355 (2006) 2542-2550
16. Scagliotti G.V., Parikh T., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced stage non small cell lung cancer. J Clin Oncol 26 (2008) 3643-3651
17. Talantov D., Baden J., and Jatkoe T. A quantitative reverse transcriptase-polymerase chain reaction array to identify metastatic carcinoma tissue of origin. J Mol Diagn 8 (2006) 320-329
18. Rosenfeld N., Aharonov R., Meiril E., et al. MicroRNAs accurately identify cancer tissue origin. Nature Biotech 26 (2008) 462-469
19. Monzon F.A., Lyons-Weiler M., Buturovic L.H., et al. Multicenter validation of the 1550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 27 (2009) 2503-2508
20. Pillai R., Deeter R., Rigl C.T., et al. Validation of a microarray based gene expression test for tumors with uncertain origins using formalin-fixed paraffin embedded (FFPE) specimens [abstract]. J Clin Oncol 27 Suppl (2009) E22015
21. Ma X.J., Pate R., Wang X., et al. Molecular classification of human cancers using a 92-gene real time quantitative polymerase chain reaction array. Arch Pathol Lab Med 130 (2006) 465-473
22. Varadhachary G., Talantov D., Rayber M., et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26 (2008) 442-448
23. Monzon F.A., Henner W.D., and Medeiros F. Use of microarray based 1550-gene expression profile of carcinoma of unknown primary (CUP). Gastrointestinal Cancer Symposium, American Society of Clinical Oncology (2009) abstract 313
24. Bridgewater J., van Laar R., Floore A., et al. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br J Cancer 98 (2008) 1425-1430
25. Horlings H., van Laar R., Kerst J.M., et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinoma of unknown primary. J Clin Oncol 26 (2008) 4435-4441
26. Greco F.A., Spigel D.R., Yardley D.A., et al. Unknown primary cancer (UPC): accuracy of tissue of origin prediction by molecular profiling [abstract]. J Clin Oncol 27 15 Suppl (2009) 11070
27. Varadhachary G., and Greco F.A. Overview of patient management and future directions in unknown primary carcinoma. Semin Oncol 36 (2009) 75-80
28. Tothill R.W., Kowalczyk A., Rischin D., et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 65 (2005) 4031-4040
29. Monzon F.A., Lyons-Weiler M., Buturovic L.J., et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol 27 (2009) 2503-2508
30. Horlings H.M., van Laar R.K., Kerst J.M., et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 26 (2008) 4435-4441
31. Greco F.A., Burris H.A., Litchy S., et al. Gemcitabine, carboplatin and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 20 (2002) 1651-1656
32. Culine S., Lortholary A., Voigt J.J., et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for The French Study Group in Carcinomas of Unknown Primary (GEFCAPI01). J Clin Oncol 21 (2003) 3479-3482
33. Seve P., Billotey C., Broussole C., et al. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 109 (2007) 292-299
34. Hainsworth J.D., and Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol 36 (2009) 44-51
35. National Comprehensive Cancer Network, Practice Guidelines in Oncology v.1.2009. Occult Primary. www.nccn.org
36. Briasoulis E., Kalofonos H., Bafakoulos D., et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group study. J Clin Oncol 18 (2000) 3101-3107
37. Lembersky B.C., and Thomas L.C. Metastases of unknown primary site. Med Clin North Am 80 (1996) 153-171
38. National Comprehensive Cancer Network, Practice Guidelines in Oncology v.1.2009. Distress Management. www.nccn.org